Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma 12Lymphoma, Large B-Cell, Diffuse 9Lymphoma, Non-Hodgkin 7Lymphoma, Large-Cell, Immunoblastic 6Lymphoma, Follicular 6Lymphoma, Large-Cell, Anaplastic 3Burkitt Lymphoma 3Lymphoma, Mantle-Cell 2Lymphoma, B-Cell, Marginal Zone 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, B-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Immunoblastic Lymphadenopathy 1Cardiotoxicity 1

Interventions

Rituximab 14pirtobrutinib 6ibrutinib 4Vincristine 4Doxorubicin 4Prednisone 3Cytarabine 3Cyclophosphamide 3zanubrutinib 2acalabrutinib 2Methotrexate 2Etoposide 2Bendamustine Hydrochloride 2venetoclax 1tositumomab I-131 1idelalisib 1ibritumomab tiuxetan 1etoposide phosphate 1entecavir 1cirmtuzumab 1axicabtagene ciloleucel 1VAP-cyclo protocol 1Tenofovir 1Radiotherapy 1Melphalan 1Ifosfamide 1Gemcitabine 1Everolimus 1Drug Therapy 1Dexamethasone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Lymphoma, B-Cell × VAP-cyclo protocol × Clear all
NCT00854568 2014-08-20

Comparison Study of Doxorubicin Versus Epirubicin-induced Cardiotoxicity in Patients With DLBCL

Fudan University

Phase 3 Completed
398 enrolled
Lymphoid

Lymphoma, Lymphoma, B-Cell, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡